The confirmatory trial is identical in design to the company's previous Phase III study, which reported positive top-line findings in March...The company expects to report top-line results from the current study in late 2013 or early 2014 and to file a new drug application with the FDA in 2014. (See BioWorld Today, March 20, 2013

Top-line survival results are expected in the fourth quarter of this year or the first quarter of 2014

These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013

The study will include 20 subjects, and top-line data are expected by year-end

Esperion disclosed top-line results from this trial in January 2013...Top-line results are expected in early 2014

Top-line data are expected in the fourth quarter

The company expects to report top-line results in mid-2014

Top-line data from the Phase III program are expected in the first quarter of 2015. (See BioWorld Today, Feb. 7, 2013

Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint

Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease...Civitas Therapeutics Inc., of Chelsea, Mass., disclosed positive top-line results from a Phase II trial of CVT-301, an inhaled formulation of levodopa (L-dopa

The company expects to report top-line results of the multicenter, randomized, double-blind, placebo-controlled, parallel group trial by year-end

Alkermes Inc., of Dublin, Ireland, said top-line data from a Phase II study showed that ALKS 5461, a drug in development to treat patients who have an inadequate response to standard therapies for clinical depression, significantly reduced depressive symptoms across a range of standard measures, including the study's primary outcome measure, the Hamilton Depression Rating Scale (p = 0.026), the Montgomery-Asberg Depression Scale (p = 0.004) and the Clinical Global Impression-Severity Scale (p

GlycoMimetics Inc., of Gaithersburg, Md., reported top-line results from a Phase II study showing that patients with vaso-occlusive crisis of sickle cell disease who were treated with GMI-1070 experienced reduction in duration of vaso-occlusive crisis, reduction in length of hospital stay and reduction in the use of narcotic pain relief

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair...Eli Lilly and Co., of Indianapolis, reported top-line data showing that the primary efficacy endpoints of noninferiority of dulaglutide, a long-acting glucagon-like

Reviva Pharmaceuticals Inc., of San Jose, Calif., reported top-line results from its Phase II REFRESH study of RP5063 in schizophrenia and schizoaffective disorder, with the dopamine serotonin stabilizer showing overall broad efficacy across the Positive and Negative Syndrome Scale total scores, as well as subscales: Positive, Negative and General Psychopathology

Navidea Biopharmaceuticals Inc., of Dublin, Ohio, disclosed top-line results from the interim analysis of its Phase III trial, NEO3-06, of the imaging agent Lymphoseek for injection in patients with head and neck squamous cell carcinoma

Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testing

Theraclone Sciences Inc., of Seattle, reported top-line data from its Phase I trial of TCN-202, a fully human monoclonal antibody, discovered using the firm's I-STAR platform and in development for treating human cytomegalovirus infection

Biodel expects to report top-line data from the trial in the third quarter